Oss, The Netherlands and Helsinki, Finland – January 23, 2018 – Innatoss Laboratories, a Dutch SME specialized in diagnostics of infectious diseases, and MediSapiens, a leading developer and provider of genomic, biomedical and health data solutions, have partnered to develop a novel Lyme borreliosis (LB) diagnostic interpretation and communication solution. The development is supported by the PERMIDES (Personalised Medicine Innovation through Digital Enterprise Solutions) project, funded by the European Union.
The partnership aims at developing a novel solution for analyzing and reporting LB diagnostics results in a convenient and readily comprehensible manner. The diagnostics of LB is complex, and often requires multiple different parallel and subsequent tests. Untreated LB can lead to serious health problems. Communicating the results in an easily understandable and actionable manner is pivotal for timely clinical decision-making.
“For the interpretation of Lyme test results, it is essential to combine the results of multiple tests from different manufacturers. A comparison with previous tests is often essential”, says Anja Garritsen, CEO of Innatoss. “With the support of PERMIDES, we will create a database that facilitates the analysis and presentation of multiple test results in a user-friendly manner. Innatoss sees such a personalized Lyme dossier as a sound basis to support treatment decisions.”
“We should be paying much more attention to how information that affects clinical decision making is conveyed”, says Marko Kuisma, CCO of MediSapiens. “The work we are doing with Innatoss is highly important. We are glad to have the opportunity to work with a leading European LB diagnostics provider, and look forward to bringing new innovations to clinical practice.”
Innatoss Laboratories is a young research-intensive organization. We’re experts on cellular testing with years of experience in the pharmaceutical and diagnostics industry. We work closely with patient organizations and university medical centers contributing to meaningful and scientifically sound innovations. Our unique combination of knowledge, experience, energy and drive is what makes us a successful, ambitious and involved organization.
Anja Garritsen, CEO
MediSapiens Ltd. is a bioinformatics company specialized in pharmaceutical research and translational genomics, providing pharmaceutical and biomedical research organizations with tools that help them design more effective personalized drugs against life-threatening diseases. Established in 2009 and based in Helsinki, Finland and Cambridge, Massachusetts, MediSapiens creates intuitive software platforms to manage, integrate, and visualize complex multi-dimensional datasets, such as genomic sequencing data. The company’s goal is to drive medicine forward by developing tools that provide scientists with a way to quickly analyze and visualize vast amounts of data and turn it into knowledge that fuels innovation.
Marko Kuisma, CCO